Next Event in the Partnering series
Collaborate and partner across complex biologics, cell therapies, and tolerance strategies to co-develop, combine resources and confidently progress past proof-of-concept
The event has now run!
Returning in 2025
Collaborate, license, and partner across ADCs, and radiopharmaceutical pipelines to reduce risks, validate technologies, and acquire clinically ready assets
Why Now?
Major moves in the pharma and biotech partnering are reshaping the landscape. With AbbVie's acquisition of ImmunoGen leading the charge in 2023, and Merck's licensing deal with Daiichi reaching unprecedented heights across three ADC programs, the market frenzy surrounding ADCs has never been hotter.
Even Eli Lilly's acquisition of Mablink, despite lacking clinical programs, underscores the feverish pace of activity in the field, breaking traditional pharma partnering trends.
For ADC companies, the challenge lies in standing out, validating their offerings, and securing clinical-ready assets amidst this whirlwind of activity.
How does one differentiate and obtain assets poised for clinical success in the next wave of deals?
Enter the ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit. This event cuts through the noise of partnership events to gather a targeted critical mass of 100+ ADC companies. It provides a platform for networking and fast-tracking the search and evaluation of earlier development assets. By significantly improving the alignment, efficiency, and yield of conversations, this summit empowers participants to navigate the complex partnering landscape with confidence.
Looking to invest, acquire, license, or partner?
For large pharma business development:
Scout novel payloads or new linker conjugation chemistry with click-release tumor specificity.
Bring disruptive science in early development into in-house pipelines to stay ahead of the curve.
For investment directors and venture partners:
Identify strategic assets with compelling data packages and gain market intelligence into big pharma interests.
Ensure investments yield returns in the dynamic ADC space.
FOR ADC COMPANY CORPORATE DEVELOPMENT
Seek alignment with pharma to validate technologies, differentiate assets, and creatively partner to raise capital and de-risk future pipelines.
